title: [Amyloidosis: Up-to-date].
abstract: Amyloidosis is mainly a systemic disease belonging to protein-folding diseases. The past 10 years have shown significant progress in typing and the clinical management of amyloidosis, in the identification of novel prognostic markers for risk-stratification, and also in the development of new therapeutic agents. Biological molecular techniques are now able to type amyloidosis which were unidentified. Cardiac MRI and biomarkers allow a precise risk-stratification, especially in AL amyloidosis. If necessary, this prognostic evaluation may lead to rapid changes in the chemotherapy treatment. Emerging treatments rely on biotherapies, gene therapy, immunotherapy and blocking analogous agents. They give hope about an increase of survival of patients with systemic amyloidosis.
authors.affiliation: Service de médecine interne, CHRU de Besançon, 3, boulevard Fleming, 25030 Besançon cedex, France; UFR sciences médicales et pharmaceutiques, université de Franche-Comté, rue Claude-Goudimel, 25000 Besançon, France. Electronic address: nadine.magy@univ-fcomte.fr.
authors.forename: N
authors.initials: N
authors.lastname: Magy-Bertrand
mesh_terms: D000686:Amyloidosis / Q000175:diagnosis* / Q000628:therapy; D015415:Biomarkers / Q000032:analysis*; D019468:Disease Management; D006801:Humans; D011379:Prognosis
chemical_list: D015415:Biomarkers
keywords: Amyloses systémiques; Diagnosis; Diagnostic; Prognosis; Pronostic; Systemic amyloidosis; Traitement; Treatment